等待開盤 06-25 09:30:00 美东时间
-0.007
-1.02%
Beauty Health ( ($SKIN) ) has shared an update. On June 17, 2026, SkinHealth Sy...
06-23 04:51
Securities Class Action On June 17, 2026, SkinHealth Systems Inc., f/k/a The Beauty Health Company (the "Company"), entered into a Stipulation and Agreement of Settlement to settle the securities class action pending in the United States District Court for the Central District of California, capti...
06-23 04:15
今日重点评级关注:Oppenheimer:维持Protara Therapeutics"跑赢大市"评级,目标价从25美元升至28美元;Piper Sandler:维持Bright Minds Biosciences"超配"评级,目标价从190美元升至220美元
05-21 12:05
Roth Capital analyst George Kelly reiterates SkinHealth Systems (NASDAQ:SKIN) with a Buy and lowers the price target from $2.5 to $2.
05-21 01:36
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Beauty Health业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 净销售额为6,490万美元,同比下降6.7%,符合6,300万至6,800万美元的指导区间 - 消耗品收入4,640万美元,同比下降6.1% - 设备系统收入1,850万美元,同比下降8.3% - 设备投放量746台,较去年同期的862台下降 **盈利能力:** - 调整后EBITDA为850万美元,同比增长17%,EBITDA利润率为13.1% - 调整后毛利率为72.2%,略高于去年同期的71.9% - GAAP毛利率为68.5%,低
05-10 12:11
Beauty Health (NASDAQ:SKIN) sees Q2 sales of $72.000 million-$77.000 million vs $76.764 million analyst estimate.
05-08 04:24
今日重点评级关注:Benchmark:维持史密斯微软件"买入"评级,目标价从2美元升至2.5美元;Citizens:维持DBV Technologies"跑赢大市"评级,目标价从47美元升至55美元
05-04 16:04
Canaccord Genuity analyst Susan Anderson maintains SkinHealth Systems (NASDAQ:SKIN) with a Hold and lowers the price target from $1.5 to $1.
05-02 06:24
SkinHealth Systems Inc. announced the appointment of three new independent directors: Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie, effective April 17, 2026. Brent Saunders, Chairman, highlighted their expertise in medtech, aesthetics, and consumer brands. Tripp brings experience in medical device manufacturing and supply chain leadership; Shridharani is a plastic surgeon and aesthetic medicine innovator; Beattie has leadership exp...
04-22 20:05
今日重点评级关注:HC Wainwright & Co.:维持Altimmune"买入"评级,目标价从12美元升至25美元;BTIG:维持Jade Biosciences"买入"评级,目标价从28美元升至39美元
03-17 11:45